

Peter A. McCullough, MD, MPH
ABIM ID: 136084

November 11, 2024

Furman S. McDonald, MD, MPH
President and CEO
Chair, Credentials and Certification Committee
American Board of Internal Medicine
510 Walnut St, Suite 1700
Philadelphia, PA 19106-3699

RE: Voluntary Termination of ABIM Maintenance of Certification in Internal Medicine, Cardiovascular Diseases, Peter Andrew McCullough ABIM #136084

Dear Dr. McDonald:

Because [ABIM Certification is voluntary](#), based on my profound disagreement with ABIM's dogmatic and arbitrary pronouncements and as a matter of conscience, please be advised that I am voluntarily ending my ABIM Maintenance of Certification in Internal Medicine, Cardiovascular Diseases.

I have determined that ABIM's statements, policies, and educational/testing material concerning pandemic response, COVID-19 vaccination, and the emergence of transgender medicine is incompatible with good clinical practice in general and specifically with my clinical and academic practice in internal medicine and cardiovascular diseases.


My expert contributions to clinical practice, research (see references below), congressional testimony, and public presentation of early multidrug therapy for high-risk acute SARS-CoV-2 infection and COVID-19 vaccine safety and theoretical efficacy are not congruent with ABIM's position(s) and my ABIM board certification. Additionally my expert contributions to the legal battle against transgender clinical programs for the youth are in conflict with the [ABIM's position on this new and harmful approach](#).

I am gravely disappointed with the ABIM's absence of education on the evolving, ambulatory, multidrug treatment of COVID-19 to prevent hospitalization and death. I am concerned about the lack of ABIM updates to its board-certified physicians on emerging data and regulatory warnings concerning COVID-19 vaccine injuries, disabilities, and death. I am also greatly concerned about the lack of ABIM attention to emerging data indicating transgender medicine in the youth results in an increased burden of psychiatric care, disfigurement, sterilization, and elevates the risk of all-cause mortality.

ABIM's COVID-19 Misinformation Policy and procedures, including its appeal procedure, are vague, arbitrary, capricious, ex post facto professional targeting and reprisal against physicians including myself without equal protection, due process, fair rules of evidence, or expert peer-review. Any pretense of fairness in the procedures is mere lip service and is belied by a shameful pattern of unjust adjudications. ABIM's conduct is resulting in suppression of data and discussion of critical information concerning early therapeutics and COVID-19 vaccine safety. "Misinformation" is a term that is itself a tool of propaganda. Instead of fostering scientific discourse, the ABIM is using propaganda to force particular sets of views concerning COVID-19 onto physicians. [For these and other violations of the law, ABIM is being sued by the Association of American Physicians and Surgeons \(AAPS v. ABIM, No. 23-40423 \(5th Cir. 2024\)\).](#) In a novel, rapidly developing pandemic, no person or organization has agency over truth nor can they declare they are the only evidence-based, consensus-driven viewpoint. The ABIM alone cannot properly determine if one is spreading information versus misinformation. All scientific data and interpretations merit the opportunity for presentation and interchange. In my view, the ABIM policy has harmed the medical community and worked to increase morbidity and mortality from SARS-CoV-2 infection due to therapeutic nihilism and denial of COVID-19 vaccine injuries, disabilities, and death. I will no longer participate with ABIM COVID-19 Misinformation policies and procedures including correspondence and hearings.

I will consider my certification periods under the maintenance of certification programs to be ended as of this date. As such, I decline to participate further in the appeal from the recommendation of the Credentials and Certification Committee; however, I reserve all rights and claims that I may have and retain vis-à-vis any adverse action ever taken against me by ABIM. I further reserve all rights granted under certification for dates of participation in the ABIM MOC program and reserve future rights of participation with other organizations recognizing training completed in internal medicine and cardiovascular diseases.

Respectfully submitted,



11-NOV-2024

Peter A. McCullough, MD, MPH
c/o Counsel, sent by certified mail

References

1. Lo KB, **McCullough** PA, Rangaswami J. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020 May;8(5):e29. doi: 10.1016/S2213-2600(20)30156-9. Epub 2020 Mar 26. PMID: 32222167; PMCID: PMC7194509.
2. **McCullough** PA, Eidt J, Rangaswami J, Lerma E, Tumlin J, Wheelan K, Katz N, Lepor NE, Vijay K, Soman S, Singh B, **McCullough** SP, **McCullough** HB, Palazzuoli A, Ruocco GM, Ronco C. Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit

- cases of SARS-CoV-2 (COVID-19) infection. *Rev Cardiovasc Med*. 2020 Mar 30;21(1):1-7. doi: 10.31083/j.rcm.2020.01.42. PMID: 32259899.
3. Kazory A, Ronco C, **McCullough** PA. SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill. *Proc (Bayl Univ Med Cent)*. 2020 Apr 16;0(0):1-6. doi: 10.1080/08998280.2020.1754700. PMID: 32336959; PMCID: PMC7171388.
 4. Gopalakrishnan A, Mossaid A, Lo KB, Vasudevan V, **McCullough** PA, Rangaswami J. Fulminant Acute Kidney Injury in a Young Patient with Novel Coronavirus 2019. *Cardiorenal Med*. 2020;10(4):217-222. doi: 10.1159/000508179. Epub 2020 May 6. PMID: 32375150; PMCID: PMC7251584.
 5. Gul F, Lo KB, Peterson J, **McCullough** PA, Goyal A, Rangaswami J. Meta-analysis of outcomes of patients with COVID-19 infection with versus without gastrointestinal symptoms. *Proc (Bayl Univ Med Cent)*. 2020 May 29;33(3):366-369. doi: 10.1080/08998280.2020.1771164. PMID: 32669979; PMCID: PMC7265105.
 6. **McCullough** PA, Arunthamakun J. Disconnect between community testing and hospitalization for SARS-CoV-2 (COVID-19) infection. *Proc (Bayl Univ Med Cent)*. 2020 May 14;33(3):481. doi: 10.1080/08998280.2020.1762439. PMID: 32675999; PMCID: PMC7340440.
 7. Briedis K, Aldujeli A, Aldujeili M, Briede K, Zaliunas R, Hamadeh A, Stoler RC, **McCullough** PA. Considerations for Management of Acute Coronary Syndromes During the SARS-CoV-2 (COVID-19) Pandemic. *Am J Cardiol*. 2020 Sep 15;131:115-119. doi: 10.1016/j.amjcard.2020.06.039. Epub 2020 Jun 30. PMID: 32723554; PMCID: PMC7324338.
 8. Hamadeh A, Aldujeli A, Briedis K, Tecson KM, Sanz-Sánchez J, Al Dujeli M, Al-Obeidi A, Diez JL, Žaliūnas R, Stoler RC, **McCullough** PA. Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. *Am J Cardiol*. 2020 Sep 15;131:1-6. doi: 10.1016/j.amjcard.2020.06.063. Epub 2020 Jul 3. PMID: 32732010; PMCID: PMC7333635.
 9. Singhanian N, Bansal S, Nimmatoori DP, Ejaz AA, **McCullough** PA, Singhanian G. Current Overview on Hypercoagulability in COVID-19. *Am J Cardiovasc Drugs*. 2020 Oct;20(5):393-403. doi: 10.1007/s40256-020-00431-z. PMID: 32748336; PMCID: PMC7398761.
 10. **McCullough** PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, **McCullough** SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. *Am J Med*. 2021 Jan;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003. Epub 2020 Aug 7. PMID: 32771461; PMCID: PMC7410805.
 11. Molnar MZ, Bhalla A, Azhar A, Tsujita M, Talwar M, Balaraman V, Sodhi A, Kadaria D, Eason JD, Hayek SS, Coca SG, Shaeff S, Neyra JA, Gupta S, Leaf DE, Kovesdy CP; STOP-COVID Investigators. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. *Am J Transplant*. 2020 Nov;20(11):3061-3071. doi: 10.1111/ajt.16280. Epub 2020 Sep 15. PMID: 32844546; PMCID: PMC7460925.
 12. Elsaid O, **McCullough** PA, Tecson KM, Williams RS, Yoon A. Ventricular Fibrillation Storm in Coronavirus 2019. *Am J Cardiol*. 2020 Nov 15;135:177-180. doi: 10.1016/j.amjcard.2020.08.033. Epub 2020 Aug 29. PMID: 32871109; PMCID: PMC7455792.
 13. Lo KB, Bhargav R, Salacup G, Pelayo J, Albano J, **McCullough** PA, Rangaswami J. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. *Expert Rev Cardiovasc Ther*. 2020 Dec;18(12):919-930. doi: 10.1080/14779072.2020.1826308. Epub 2020 Oct 5. PMID: 32945216.
 14. Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, Neyra JA, Rashidi A, Boyle SM, Anand S, Christov M, Thomas LF, Edmonston D, Leaf DE; STOP-COVID Investigators. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. *Am J Kidney Dis*. 2021 Feb;77(2):190-203.e1. doi: 10.1053/j.ajkd.2020.09.003. Epub 2020 Sep 19. PMID: 32961244; PMCID: PMC7501875.

15. **McCullough PA.** Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). *Antimicrob Agents Chemother.* 2020 Nov 17;64(12):e02017-20. doi: 10.1128/AAC.02017-20. PMID: 32967849; PMCID: PMC7674042.
16. Ruocco G, **McCullough PA**, Tecson KM, Mancone M, De Ferrari GM, D'Ascenzo F, De Rosa FG, Paggi A, Forleo G, Secco GG, Pistis G, Monticone S, Vicenzi M, Rota I, Blasi F, Pugliese F, Fedele F, Palazzuoli A. Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. *Am J Cardiol.* 2020 Dec 15;137:111-117. doi: 10.1016/j.amjcard.2020.09.029. Epub 2020 Sep 28. PMID: 32991860; PMCID: PMC7521434.
17. Palazzuoli A, Mancone M, De Ferrari GM, Forleo G, Secco GG, Ruocco GM, D'Ascenzo F, Monticone S, Paggi A, Vicenzi M, Palazzo AG, Landolina M, Taravelli E, Tavazzi G, Blasi F, Infusino F, Fedele F, De Rosa FG, Emmett M, Schussler JM, Tecson KM, **McCullough PA.** Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. *J Am Heart Assoc.* 2020 Nov 17;9(22):e017364. doi: 10.1161/JAHA.120.017364. Epub 2020 Oct 7. PMID: 33023356; PMCID: PMC7763715.
18. Zhang J, Tecson KM, **McCullough PA.** Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. *Rev Cardiovasc Med.* 2020 Sep 30;21(3):315-319. doi: 10.31083/j.rcm.2020.03.126. PMID: 33070537.
19. Zhang J, **McCullough PA**, Tecson KM. Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19. *Rev Cardiovasc Med.* 2020 Sep 30;21(3):339-344. doi: 10.31083/j.rcm.2020.03.131. PMID: 33070539.
20. Mahajan P, Dass B, Radhakrishnan N, **McCullough PA.** COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature. *Cardiorenal Med.* 2020;10(6):462-469. doi: 10.1159/000511800. Epub 2020 Oct 22. PMID: 33091905; PMCID: PMC7649692.
21. **McCullough PA**, Oskoui R. Early multidrug regimens in new potentially fatal medical problems. *Rev Cardiovasc Med.* 2020 Dec 30;21(4):507-508. doi: 10.31083/j.rcm.2020.04.270. PMID: 33387995.
22. **McCullough PA**, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, Berkowitz RL, Berry AC, Borody TJ, Brewer JH, Brufsky AM, Clarke T, Derwand R, Eck A, Eck J, Eisner RA, Fareed GC, Farella A, Fonseca SNS, Geyer CE Jr, Gonnering RS, Graves KE, Gross KBV, Hazan S, Held KS, Hight HT, Immanuel S, Jacobs MM, Ladapo JA, Lee LH, Littell J, Lozano I, Mangat HS, Marble B, McKinnon JE, Merritt LD, Orient JM, Oskoui R, Pompan DC, Procter BC, Prodromos C, Rajter JC, Rajter JJ, Ram CVS, Rios SS, Risch HA, Robb MJA, Rutherford M, Scholz M, Singleton MM, Tumlin JA, Tyson BM, Urso RG, Victory K, Vliet EL, Wax CM, Wolkoff AG, Wooll V, Zelenko V. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). *Rev Cardiovasc Med.* 2020 Dec 30;21(4):517-530. doi: 10.31083/j.rcm.2020.04.264. PMID: 33387997.
23. Procter BC, Ross C, Pickard V, Smith E, Hanson C, **McCullough PA.** Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. *Rev Cardiovasc Med.* 2020 Dec 30;21(4):611-614. doi: 10.31083/j.rcm.2020.04.260. PMID: 33388006.
24. Palazzuoli A, Ruocco G, Tecson KM, **McCullough PA.** Screening, detection, and management of heart failure in the SARS-CoV2 (COVID-19) pandemic. *Heart Fail Rev.* 2021 Jul;26(4):973-979. doi: 10.1007/s10741-020-10068-4. Epub 2021 Jan 6. PMID: 33405001; PMCID: PMC7786335.
25. **McCullough PA.** Regarding: "Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019". *Ann Med.* 2021 Dec;53(1):286. doi: 10.1080/07853890.2021.1872094. PMID: 33439042; PMCID: PMC7877973.
26. Aldujeli A, Hamadeh A, Tecson KM, Krivickas Z, Maciulevicius L, Stikloraitis S, Sukys M, Briedis K, Aldujeili M, Briede K, Braukyliene R, Pranculis A, Unikis R, Zaliaduonyte D, **McCullough PA.** Six-Month Outcomes for COVID-19 Negative Patients with Acute Myocardial Infarction Before Versus During the COVID-19 Pandemic. *Am J Cardiol.* 2021 May 15;147:16-22. doi: 10.1016/j.amjcard.2021.01.043. Epub 2021 Feb 23. PMID: 33631113; PMCID: PMC7900754.
27. Zhang J, Tecson KM, **McCullough PA.** Role of endothelial cell receptors in the context of SARS-CoV-2 infection (COVID-19). *Proc (Bayl Univ Med Cent).* 2021 Jan 26;34(2):262-268. doi: 10.1080/08998280.2021.1874231. PMID: 33664552; PMCID: PMC7852287.

28. **McCullough PA**, Vijay K. SARS-CoV-2 infection and the COVID-19 pandemic: a call to action for therapy and interventions to resolve the crisis of hospitalization, death, and handle the aftermath. *Rev Cardiovasc Med*. 2021 Mar 30;22(1):9-10. doi: 10.31083/j.rcm.2021.01.301. PMID: 33792243.
29. **McCullough PA**. The Reply. *Am J Med*. 2021 Apr;134(4):e298. doi: 10.1016/j.amjmed.2020.11.028. PMID: 33888224; PMCID: PMC8054639.
30. **McCullough PA**. The Reply. *Am J Med*. 2021 May;134(5):e343-e344. doi: 10.1016/j.amjmed.2021.01.011. PMID: 33962708; PMCID: PMC8095713.
31. **McCullough PA**. The Reply. *Am J Med*. 2021 May;134(5):e346-e347. doi: 10.1016/j.amjmed.2021.01.013. PMID: 33962710; PMCID: PMC8095728.
32. Alexander PE, Armstrong R, Fareed G, Lotus J, Oskoui R, Prodromos C, Risch HA, Tenenbaum HC, Wax CM, Dara P, **McCullough PA**, Gill KK. Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents. *Med Hypotheses*. 2021 Aug;153:110622. doi: 10.1016/j.mehy.2021.110622. Epub 2021 Jun 5. PMID: 34130113; PMCID: PMC8178530.
33. Palazzuoli A, Tecson KM, **McCullough PA**. Impact of renin-angiotensin-aldosterone system inhibitor continuation on outcomes for patients with severe coronavirus disease 2019 manifestations. *J Hypertens*. 2021 Aug 1;39(8):1725-1726. doi: 10.1097/HJH.0000000000002876. PMID: 34188007.
34. Safder T, **McCullough PA**, Wheelan KR, Rahimi G, Zurawski S, Zurawski G, Gu J, Wang X, Balaji U, Berhe M, Clariday L, Baker R, Chionh K, Carino G, Sandkovsky US. Screening for SARS-CoV-2 via PCR and serological testing in asymptomatic healthcare workers. *Proc (Bayl Univ Med Cent)*. 2021 Mar 30;34(4):437-441. doi: 10.1080/08998280.2021.1895959. PMID: 34219921; PMCID: PMC8224198.
35. Santin AD, Scheim DE, **McCullough PA**, Yagisawa M, Borody TJ. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. *New Microbes New Infect*. 2021 Aug 3;43:100924. doi: 10.1016/j.nmni.2021.100924. PMID: 34466270; PMCID: PMC8383101.
36. **McCullough PA**, Stricker RB, Risch HA. Role of hydroxychloroquine in multidrug treatment of COVID-19. *Rev Cardiovasc Med*. 2021 Sep 24;22(3):545-546. doi: 10.31083/j.rcm.2203063. PMID: 34565055.
37. Fazio S, Bellavite P, Zanolin E, **McCullough PA**, Pandolfi S, Affuso F. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021. *Med Sci Monit*. 2021 Dec 30;27:e935379. doi: 10.12659/MSM.935379. PMID: 34966165; PMCID: PMC8725339.
38. Palazzuoli A, Tecson KM, Vicenzi M, D'Ascenzo F, De Ferrari GM, Monticone S, Secco GG, Tavazzi G, Forleo G, Severino P, Fedele F, De Rosa F, **McCullough PA**. Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19. *Am J Cardiol*. 2022 Mar 15;167:133-138. doi: 10.1016/j.amjcard.2021.12.004. Epub 2022 Jan 10. PMID: 35027137; PMCID: PMC8744009.
39. Seneff S, Nigh G, Kyriakopoulos AM, **McCullough PA**. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. *Food Chem Toxicol*. 2022 Jun;164:113008. doi: 10.1016/j.fct.2022.113008. Epub 2022 Apr 15. PMID: 35436552; PMCID: PMC9012513.
40. Palazzuoli A, Lavie CJ, Severino P, Dastidar A, Sammut E, **McCullough PA**. Co-Management of COVID-19 and Heart Failure During the COVID-19 Pandemic: Lessons Learned. *Rev Cardiovasc Med*. 2022 Jun 16;23(6):218. doi: 10.31083/j.rcm.2306218. PMID: 39077163; PMCID: PMC11273677.
41. Hazan S, Dave S, Borody TJ, **McCullough PA**. Letter in reply: more power to ivermectin multidrug therapy. *Future Microbiol*. 2022 Nov;17:1283-1285. doi: 10.2217/fmb-2022-0184. Epub 2022 Sep 22. PMID: 36134721.
42. Kyriakopoulos AM, Nigh G, **McCullough PA**, Seneff S. Mitogen Activated Protein Kinase (MAPK) Activation, p53, and Autophagy Inhibition Characterize the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein Induced Neurotoxicity. *Cureus*. 2022 Dec 9;14(12):e32361. doi: 10.7759/cureus.32361. PMID: 36514706; PMCID: PMC9733976.

43. Palazzuoli A, Beltrami M, **McCullough** PA. Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care. *Biomedicines*. 2023 Mar 6;11(3):790. doi: 10.3390/biomedicines11030790. PMID: 36979769; PMCID: PMC10045184.
44. Polykretis P, Donzelli A, Lindsay JC, Wiseman D, Kyriakopoulos AM, Mörz M, Bellavite P, Fukushima M, Seneff S, **McCullough** PA. Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues. *Autoimmunity*. 2023 Dec;56(1):2259123. doi: 10.1080/08916934.2023.2259123. PMID: 37710966.
45. Thorp JA, Rogers C, Deskevich MP, Tankersley S, Benavides A, Redshaw MD, **McCullough** PA. Increased risk of fetal loss after COVID-19 vaccination. *Hum Reprod*. 2023 Dec 4;38(12):2536. doi: 10.1093/humrep/dead204. PMID: 37823793; PMCID: PMC10694405.
46. Kyriakopoulos AM, Nigh G, **McCullough** PA, Olivier MD, Seneff S. Bell's palsy or an aggressive infiltrating basaloid carcinoma post-mRNA vaccination for COVID-19? A case report and review of the literature. *EXCLI J*. 2023 Sep 11;22:992-1011. doi: 10.17179/excli2023-6145. PMID: 37927346; PMCID: PMC10620857.
47. Hulscher N, Procter BC, Wynn C, **McCullough** PA. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination. *Cureus*. 2023 Nov 21;15(11):e49204. doi: 10.7759/cureus.49204. PMID: 38024037; PMCID: PMC10663976.
48. Brouqui P, Million M, Parola P, **McCullough** PA, Raoult D. Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients. *New Microbes New Infect*. 2023 Oct 30;55:101188. doi: 10.1016/j.nmni.2023.101188. PMID: 38024333; PMCID: PMC10651676.
49. Hulscher N, Hodgkinson R, Makis W, **McCullough** PA. Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis. *ESC Heart Fail*. 2024 Jan 14. doi: 10.1002/ehf2.14680. Epub ahead of print. PMID: 38221509.
50. Rose J, Hulscher N, **McCullough** PA. Determinants of COVID-19 vaccine-induced myocarditis. *Ther Adv Drug Saf*. 2024 Jan 27;15:20420986241226566. doi: 10.1177/20420986241226566. PMID: 38293564; PMCID: PMC10823859.
51. Polykretis P, **McCullough** PA. Rational harm-benefit assessments by age group are required for continued COVID-19 vaccination. *Scand J Immunol*. 2023 Jul;98(1):e13242. doi: 10.1111/sji.13242. Epub 2022 Dec 28. PMID: 38441161; PMCID: PMC9877705.
52. Jean-François Lesgards, Dominique Cerdan, Christian Perronne, Jean-Marc Sabatier, Xavier Azalbert, Elizabeth A. Rodgers, **Peter A. McCullough**. Toxicity of SARS-CoV-2 Spike Protein with Respiratory Infection and Produced from COVID-19 mRNA and Adenoviral DNA Vaccines. *Archives of Microbiology and Immunology*. 7 (2023): 121-138.
53. Hulscher N, Hodgkinson R, Makis W, **McCullough** PA. Response to: Van Wyk et al. letter to the editor regarding 'Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis'. *ESC Heart Fail*. 2024 Aug;11(4):2476-2478. doi: 10.1002/ehf2.14861. Epub 2024 May 21. PMID: 38772619; PMCID: PMC11287309.
54. Hulscher N, Hodgkinson R, Makis W, **McCullough** PA. Response to: Szuster-Ciesielska, letter to the editor regarding 'Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis'. *ESC Heart Fail*. 2024 Aug;11(4):2479-2480. doi: 10.1002/ehf2.14862. Epub 2024 May 22. PMID: 38773951; PMCID: PMC11287320.
55. Boros LG, Kyriakopoulos AM, Brogna C, Piscopo M, **McCullough** PA, Seneff S. Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. *Pharmacol Res Perspect*. 2024 Jun;12(3):e1218. doi: 10.1002/prp2.1218. PMID: 38867495; PMCID: PMC11169277.
56. Hulscher, N.; **McCullough**, P. A. Delayed Fatal Pulmonary Hemorrhage Following COVID-19 Vaccination: Case Report, Batch Analysis, And Proposed Autopsy Checklist. *Preprints* 2024, 2024021096. <https://doi.org/10.20944/preprints202402.1096.v1>
57. **McCullough**, P.; Hulscher, N. Risk Stratification for Future Cardiac Arrest after COVID-19 Vaccination. *Preprints* 2024, 2024080821. <https://doi.org/10.20944/preprints202408.0821.v1>

58. Nicolas Hulscher, B., Paul E. Alexander, P., Richard Amerling, M., Heather Gessling, M., Roger Hodkinson, M., William Makis, M., Harvey A. Risch, MD, PhD, Mark Trozzi, M., & Peter A. **McCullough**, MD, MPH. (2023). A SYSTEMATIC REVIEW OF AUTOPSY FINDINGS IN DEATHS AFTER COVID-19 VACCINATION. ASM Microbe 2024, Atlanta, GA.
Zenodo. <https://doi.org/10.5281/zenodo.8120771>
59. Mead, M. N., Seneff, S., Wolfinger, R., Rose, J., Denhaerynck, K., Kirsch, S., & **McCullough, P. A.** (2024). COVID-19 Modified mRNA "Vaccines" Part 1: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex. International Journal of Vaccine Theory, Practice, and Research, 3(2), 1112–1178. <https://doi.org/10.56098/fdrasy50>
60. Mead, M. N., Seneff, S., Rose, J., Wolfinger, R., Hulscher, N., & **McCullough, P. A.** (2024). COVID-19 Modified mRNA "Vaccines": Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2. International Journal of Vaccine Theory, Practice, and Research, 3(2), 1246–1315. <https://doi.org/10.56098/w66wjg87>
61. Halma, M.; Rose, J.; **McCullough, P.** Inadvertent Exposure to Pharmacologically Designed Lipid Nanoparticles Via Bodily Fluids: Biologic Plausibility and Potential Consequences. Preprints 2024, 2024021267. <https://doi.org/10.20944/preprints202402.1267.v1>, ID: ppzbmed-10.20944.preprints202402.1267.v1
62. Cosgrove K, Thorp JA, Milhoan KA, **McCullough PA.** Comparative Risks Cardiovascular Adverse Events of COVID-19 and other Vaccines. G Med Sci. 2024;5(1):50-60.
<https://www.doi.org/10.46766/thegms.pubheal.24160201>
63. Anthony M Kyriakopoulos, Greg Nigh, **Peter A McCullough**, et al. Oncogenesis and autoimmunity as a result of mRNA COVID-19 vaccination. Authorea. April 23, 2024. DOI: 10.22541/au.171387387.73158754/v1
64. Kyriakopoulos AM, Nigh G, **McCullough PA** and Seneff S. Clinical rationale for dietary lutein supplementation in post COVID-19 and mRNA vaccine injury syndromes. F1000Research 2024, 13:191 (<https://doi.org/10.12688/f1000research.143517.1>)
65. **McCullough PA.** (2021) Multifaceted Highly Targeted Sequential Multidrug Treatment of Early Ambulatory High-Risk SARS-CoV-2 Infection (COVID-19). J Infect Dis Res, 4(S1): 10.
66. Hulscher N, Alexander P, Amerling R, Gessling H, Hodkinson R, Makis W, Risch H, Trozzi M, **McCullough P.** A Systematic Review of Autopsy Findings in Deaths after COVID-19 Vaccination [abstract]. ASM Microbe 2024; Jun 14 2024; Atlanta, GA. Available from: <https://www.abstractsonline.com/pp8/#!/20188/presentation/4860>.
67. Rogers, C., Kirstin Cosgrove and **Peter McCullough.** 2024 "COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes" Preprints. International Journal of Innovative Research in Medical Science Volume 09, Issue 11, November 2024, <https://doi.org/10.20944/preprints202406.1236.v1>
<https://ijirms.in/index.php/ijirms/article/view/1982/1420>

Knox Street Postal Center
2310 N. Henderson / Dallas, TX 75206
214-528-6655 fax: 214-838-9281

knoxstreetpostalcenter@gmail.com

16.51

USPS First Class Mail
70221670000174699230
19106 -3699
Philadelphia Pa

16.51
0.00
16.51
16.51

SUBTOTAL
TAX
TOTAL
TEND Credit Card

Total shipments: 0
Customer: None selected

11/12/2024
09:24 AM

#179978
Workstation: 0 - Master Workstation

Thank you for your business! Follow us on Instagram @ksp_center7

7022 1670 0001 7469 9230

U.S. Postal ServiceTM
CERTIFIED MAIL[®] RECEIPT
Domestic Mail Only

For delivery information, visit our website at www.usps.com.

OFFICIAL USE

Certified Mail Fee

\$

Extra Services & Fees (check box, add fee as appropriate)

☐ Return Receipt (hardcopy) \$
☐ Return Receipt (electronic) \$
☐ Certified Mail Restricted Delivery \$
☐ Adult Signature Required \$
☐ Adult Signature Restricted Delivery \$

Postage

\$

Total Postage and Fees

\$

Sent To Furman McDonald, ABIM

Street and Apt. No., or PO Box No. 510 Walnut St, Sk 1700

City, State, ZIP+4[®] Philadelphia, PA 19106-3699

See Reverse for Instructions

PS Form 3800, April 2015 PSN 7530-02-000-9047


Postmark
Here

SENDER: COMPLETE THIS SECTION

- Complete items 1, 2, and 3.
- Print your name and address on the reverse so that we can return the card to you.
- Attach this card to the back of the mailpiece, or on the front if space permits.

1. Article Addressed to:

*Furman S. McDonald, M.D., MPH
or designee
American Board of Internal Medicine
510 Walnut St., St. 1700
Philadelphia, PA 19106-3699*



9590 9402 6556 1028 4797 97

2. Article Number (Transfer from service label)

7022 1670 0001 7469 9230

PS Form 3811, July 2020 PSN 7530-02-000-9053

COMPLETE THIS SECTION ON DELIVERY

A. Signature

Harold Powell

☐ Agent

☐ Addressee

B. Received by (Printed Name)

Canal

C. Date of Delivery

D. Is delivery address different from item 1? ☐ Yes

If YES, enter delivery address below: ☐ No

3. Service Type

- ☐ Adult Signature
- ☐ Adult Signature Restricted Delivery
- ☐ Certified Mail®
- ☐ Certified Mail Restricted Delivery
- ☐ Collect on Delivery
- ☐ Collect on Delivery Restricted Delivery
- ☐ Insured Mail
- ☐ Insured Mail Restricted Delivery
- ☐ Priority Mail Express®
- ☐ Registered Mail™
- ☐ Registered Mail Restricted Delivery
- ☐ Signature Confirmation™
- ☐ Signature Confirmation Restricted Delivery

Domestic Return Receipt